The ethical questions surrounding the recruitment of patients for clinical trials become more complicated when the recruiting physicians receive financial benefits for each patient enrolled.
Two physicians assert that pharmaceutical companies' sponsorship of clinical conferences for residents and physicians represent a conflict of interest.
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.
In April 2002, many pharmaceutical companies adopted PhRMA code, an attempt to self-regulate the pharmaceutical industry's marketing to physicians and other health care professionals.
Sterling Johnson joins Ethics Talk to discuss his article, coauthored with Dr Kimberly L. Sue: "Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies.”
Dr Oluwole Jegede joins Ethics Talk to discuss his article, coauthored with Drs Julio C. Nunes, Terence Tumenta, Carmen Black, and Joao P. DeAquino: “What Would Equitable Harm Reduction Look Like?”
Dr Elizabeth Salisbury-Afshar joins Ethics Talk to discuss her article, coauthored with Drs Catherine J. Livingston and Ricky N. Bluthenthal: “How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder?”
Dr Ellen L. Edens joins Ethics Talk to discuss her article, coauthored with Drs Gabriela Garcia Vassallo and Robert Heimer: "How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice?”